Synopsis
Apply the correct pregnancy, transplant or cancer-related neutropenic pathway to urinary infection, with population-specific urgency, antimicrobial safety and follow-up.
- Treat detected significant asymptomatic bacteriuria in pregnancy using culture and a pregnancy-appropriate regimen; this treatment rule does not itself define an antenatal screening schedule. If upper infection instead requires intravenous cefuroxime, exclude cefuroxime or other cephalosporin hypersensitivity and severe hypersensitivity to another beta lactam.
- An unwell person receiving anticancer treatment may have neutropenic sepsis without a striking fever; arrange emergency assessment and immediate empirical treatment without waiting for the neutrophil result.
- For pregnant or recently pregnant patients aged sixteen or over who need sepsis fluid resuscitation, NG255 uses 500 ml crystalloid containing sodium 130–154 mmol/litre in under fifteen minutes, followed by reassessment.
Key red flags
New altered mental state, marked tachypnoea, hypotension, tachycardia or reduced urine output can indicate high-risk illness. Use NG255’s maternal risk criteria and urgent obstetric and senior assessment rather than substituting an adult NEWS2 threshold.
Ask when anticancer treatment was given and whether the patient feels acutely unwell. Neutropenic sepsis can occur with a neutrophil count at or below 0.5 × 10⁹/litre and fever above 38°C or other clinically significant sepsis features; do not wait for confirmation before initial emergency treatment.
Reasoning priorities
Identify an organism and select a suitable maternal treatment.
Obtain a midstream sample before antibiotics for symptomatic infection, and use significant detected bacteriuria to guide treatment even without symptoms. Mixed growth should prompt assessment of specimen quality; this recommendation does not prescribe when all pregnant people must be screened.
Worked reasoning
A twenty four week pregnant woman has significant bacteriuria found during an individually indicated urine assessment.
- She has no dysuria, flank pain or fever and normal observations. Culture shows pure significant Escherichia coli growth, resistant to nitrofurantoin but susceptible to cefalexin. She has no beta lactam allergy, known renal disease or other evidence of an upper tract infection.
- She receives cefalexin 500 mg orally twice daily for seven days, with the positive culture and pregnancy treatment indication explained. She is told to seek prompt assessment for fever, loin pain, vomiting or feeling systemically unwell rather than assuming the existing bladder regimen covers every later syndrome.
- The obstetric team checks that she has completed treatment without a reaction. Because of her previous pyelonephritis history, it arranges an individual follow-up culture, which shows no growth; she remains clinically well.
- The result closes this episode and is shared with her maternity team. The case-specific follow-up specimen is not presented as a universal national test-of-cure or screening schedule, and further testing follows her ongoing clinical and maternity assessment.
A stable renal transplant recipient has bacterial growth without new symptoms or graft dysfunction.